Last 12 months
Inside the activity.
1 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 163 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 13 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596 Underlying: Common Stock · 163 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F8 · shares: This award was previously reported as covering 870 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F8 · derivative.underlying_shares: This award was previously reported as covering 870 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F8 · balance_after: This award was previously reported as covering 870 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 76 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 12 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208 Underlying: Common Stock · 76 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 402 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 402 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F7 · balance_after: This award was previously reported as covering 402 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
OtherRestricted Stock Unit · Derivative | 128 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 11 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 Underlying: Common Stock · 128 shares Expires 2018-02-23 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
OtherRestricted Stock Unit · Derivative | 131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 10 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 759 Underlying: Common Stock · 131 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
OtherRestricted Stock Unit · Derivative | 143 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · derivative · entry 9 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121 Underlying: Common Stock · 143 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 3 | $274.76 | $824.28 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 8 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,504.8231 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 121 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 7 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,507.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 8 | $274.76 | $2,198.08 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 6 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386.8231 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 321 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 5 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,394.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 53 | $287.63 | $15,244.39 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 4 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,073.8231 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 163 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 3 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,126.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 25 | $284.75 | $7,118.75 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 2 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963.8231 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:18 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 76 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009812 · form4.xml · nonDerivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,988.8231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,494 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 8 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,392 Underlying: Common Stock · 1,494 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F7 · balance_after: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
Exercise / conversionRestricted Stock Unit · Derivative | 570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 7 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,522 Underlying: Common Stock · 570 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F6 · shares: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F6 · derivative.underlying_shares: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F6 · balance_after: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
OtherRestricted Stock Unit · Derivative | 952 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 6 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092 Underlying: Common Stock · 952 shares Expires 2018-02-23 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
OtherRestricted Stock Unit · Derivative | 1,198 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 5 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 Underlying: Common Stock · 1,198 shares Expires 2019-02-22 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
Tax withholdingCommon Stock | 485 | $287.63 | $139,500.55 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 4 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,752 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
Exercise / conversionCommon Stock | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 3 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
Tax withholdingCommon Stock | 253 | $284.75 | $72,041.75 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,743 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
Exercise / conversionCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
OtherRestricted Stock Unit · Derivative | 1 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 16 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F11 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 15 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 2,300 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F10 · shares: This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F11 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). F10 · balance_after: This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 14 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,174 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F9 · shares: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F9 · derivative.underlying_shares: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F9 · balance_after: This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,494 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 13 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,392 Underlying: Common Stock · 1,494 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F8 · shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F8 · derivative.underlying_shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F8 · balance_after: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionRestricted Stock Unit · Derivative | 728 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 12 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948 Underlying: Common Stock · 728 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 F7 · balance_after: This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
OtherRestricted Stock Unit · Derivative | 1,216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 11 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676 Underlying: Common Stock · 1,216 shares Expires 2018-02-23 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
OtherRestricted Stock Unit · Derivative | 1,198 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 10 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 Underlying: Common Stock · 1,198 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
OtherRestricted Stock Unit · Derivative | 1,378 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · derivative · entry 9 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,174 Underlying: Common Stock · 1,378 shares Expires 2017-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Tax withholdingCommon Stock | 1,083 | $274.76 | $297,565.08 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 8 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,177 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 7 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Tax withholdingCommon Stock | 553 | $274.76 | $151,942.28 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 6 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,960 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionCommon Stock | 1,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 5 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Tax withholdingCommon Stock | 485 | $287.63 | $139,500.55 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 4 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,339 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionCommon Stock | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 3 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Tax withholdingCommon Stock | 335 | $284.75 | $95,391.25 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 2 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC |
DiPietro KennethEVP Human Resources
|
Exercise / conversionCommon Stock | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009803 · form4.xml · nonDerivative · entry 1 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:18 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
PurchaseCommon Stock | 1,333 | $285.39 | $380,424.87 |
DisclosureSEC source: 0001127602-17-009254 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433.931 F1 · kind: Purchase pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 100.9310 shares acquired under the Biogen Inc. employee stock purchase plan on 09/30/16 and 12/30/16. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:35 UTC |
ALEXANDER SUSAN HEVP, Chief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 8,160 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007118 · form4.xml · derivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 Underlying: Common Stock · 8,160 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:32 UTC |
Sandrock AlfredEVP CMO Neuro & Neurodegenerat
|
GrantRestricted Stock Unit · Derivative | 6,380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007117 · form4.xml · derivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380 Underlying: Common Stock · 6,380 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:30 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 25,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007116 · form4.xml · derivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:28 UTC |
Clancy Paul JExecutive VP and CFO
|
GrantRestricted Stock Unit · Derivative | 7,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007115 · form4.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Common Stock · 7,650 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:26 UTC |
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff
|
GrantRestricted Stock Unit · Derivative | 5,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007114 · form4.xml · derivative · entry 1 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:24 UTC |
COVINO GREGORY FVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 770 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007113 · form4.xml · derivative · entry 1 COVINO GREGORY F · CIK 0001224116 · VP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770 Underlying: Common Stock · 770 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:22 UTC |
Ehlers Michael DEVP, Research and Development
|
GrantRestricted Stock Unit · Derivative | 8,160 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007110 · form4.xml · derivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 Underlying: Common Stock · 8,160 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:19 UTC |
McKenzie PaulEVP Pharmaceutical Oper & Tech
|
GrantRestricted Stock Unit · Derivative | 7,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007109 · form4.xml · derivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010 Underlying: Common Stock · 7,010 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:17 UTC |
DiPietro KennethEVP Human Resources
|
GrantRestricted Stock Unit · Derivative | 6,380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007108 · form4.xml · derivative · entry 1 DiPietro Kenneth · CIK 0001540188 · EVP Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380 Underlying: Common Stock · 6,380 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:15 UTC |
PANGIA ROBERT WDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,450 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0001127602-17-001434 · form4.xml · derivative · entry 3 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,450 shares Expires 2017-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · derivative.exercise_date: Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:15 UTC |
PANGIA ROBERT WDirector
|
SaleCommon Stock | 5,450 | $295.39 | $1,609,875.50 |
DisclosureSEC source: 0001127602-17-001434 · form4.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,628 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:15 UTC |
PANGIA ROBERT WDirector
|
Exercise / conversionCommon Stock | 5,450 | $52.22 | $284,599.00 |
DisclosureSEC source: 0001127602-17-001434 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.